# Managed Access Programs for LDK378, Ceritinib

> **NCT05100134** · — · NO_LONGER_AVAILABLE · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Anaplastic Lymphoma Kinase (ALK)- Positive Tumors
- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** ceritinib

## Key facts

- **NCT ID:** NCT05100134
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05100134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05100134, "Managed Access Programs for LDK378, Ceritinib". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05100134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*